{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T02:31:43Z","timestamp":1778553103079,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.euroneuro.2011.10.004","type":"journal-article","created":{"date-parts":[[2011,12,5]],"date-time":"2011-12-05T19:30:35Z","timestamp":1323113435000},"page":"431-440","source":"Crossref","is-referenced-by-count":28,"title":["Effects of poloxamer 407-induced hyperlipidemia on the pharmacokinetics of carbamazepine and its 10,11-epoxide metabolite in rats: Impact of decreased expression of both CYP3A1\/2 and microsomal epoxide hydrolase"],"prefix":"10.1016","volume":"22","author":[{"given":"Young Sun","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Geon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inchul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung Gull","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Eun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2011.10.004_bb0005","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1021\/jm00388a004","article-title":"The metabolism of carbamazepine in humans: steric course of the enzymatic hydrolysis of the 10,11-epoxide","volume":"30","author":"Bellucci","year":"1987","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0010","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/jps.2600730617","article-title":"Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis","volume":"73","author":"Boudinot","year":"1984","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0015","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein\u2013dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0020","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/BF01062108","article-title":"Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level\u2013time curve","volume":"6","author":"Chiou","year":"1978","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0025","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0076-6879(95)49031-0","article-title":"Analysis of enzyme progress curves by nonlinear regression","volume":"249","author":"Duggleby","year":"1995","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0035","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0022-3565(24)35087-6","article-title":"Pharmacokinetics and pharmacodynamics of nifedipine in untreated and atorvastatin-treated hyperlipidemic rats","volume":"291","author":"Eliot","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0040","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1023\/A:1018896912889","article-title":"Effects of hyperlipidemia on the pharmacokinetics of nifedipine in the rat","volume":"16","author":"Eliot","year":"1999","journal-title":"Pharm. Res."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0045","series-title":"Pharmacokinetics","author":"Gibaldi","year":"1982"},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0050","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1124\/dmd.104.002824","article-title":"Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats","volume":"33","author":"Hidaka","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0055","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1734-1140(09)70082-9","article-title":"Atherosclerotic risk among children taking antiepileptic drugs","volume":"61","author":"Jakubus","year":"2009","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0060","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/0006-2952(93)90668-M","article-title":"Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat","volume":"46","author":"Johnston","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0065","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1002\/jps.21702","article-title":"Pharmacokinetics of liquiritigenin in mice, rats, rabbits, and dogs, and animal scale-up","volume":"98","author":"Kang","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0070","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/0006-2952(94)90071-X","article-title":"Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation","volume":"47","author":"Kerr","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0075","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/S0006-2952(96)00505-9","article-title":"Expression of glutathione S-transferases Ya, Yb1, Yb2, Yc1 and Yc2 and microsomal epoxide hydrolase genes by thiazole, benzothiazole and benzothiadiazole","volume":"52","author":"Kim","year":"1996","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0080","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0090-9556(24)02972-6","article-title":"Differences in the pharmacokinetics of peroxisome proliferator-activated receptor agonists in genetically obese Zucker and Sprague\u2013Dawley rats: implications of decreased glucuronidation in obese Zucker rats","volume":"32","author":"Kim","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0085","doi-asserted-by":"crossref","first-page":"G372","DOI":"10.1152\/ajpgi.90524.2008","article-title":"Liquiritigenin, a flavonoid aglycone from licorice, has a choleretic effect and the ability to induce hepatic transporters and phase-II enzymes","volume":"296","author":"Kim","year":"2009","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0090","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0022-3565(25)20748-0","article-title":"Interindividual and interspecies variation in hepatic microsomal epoxide hydrolase activity: studies with cis-stilbene oxide, carbamazepine 10, 11-epoxide and naphthalene","volume":"278","author":"Kitteringham","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0095","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.2042-7158.2010.01245.x","article-title":"Pharmacokinetics of clomipramine, an antidepressant, in poloxamer 407-induced hyperlipidaemic model rats","volume":"63","author":"Kobuchi","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0100","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/j.1552-4604.1993.tb01962.x","article-title":"In vivo determinations of carbamazepine and carbamazepine-10, 11-epoxide binding parameters to serum proteins in monotherapy patients","volume":"33","author":"Kodama","year":"1993","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0225","first-page":"37","article-title":"Severe hypertriglyceridemia as a carbamazepine-induced paradoxical effect","volume":"11","author":"Kowacs","year":"2005","journal-title":"J. Epilepsy Clin. Neurophysiol."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0110","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s11095-008-9610-7","article-title":"Telithromycin pharmacokinetics in rat model of diabetes mellitus induced by alloxan or streptozotocin","volume":"25","author":"Lee","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0115","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3109\/00498254.2011.580019","article-title":"Effects of experimental hyperlipidaemia on the pharmacokinetics of docetaxel in rats","volume":"41","author":"Lee","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0120","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s11095-006-0276-8","article-title":"Acute P-407 administration to mice causes hypercholesterolemia by inducing cholesterolgenesis and down-regulating low-density lipoprotein receptor expression","volume":"23","author":"Leon","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0090-9556(25)07827-4","article-title":"Metabolism of carbamazepine","volume":"10","author":"Lertratanangkoon","year":"1982","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0130","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0090-9556(25)07375-1","article-title":"Bioactivation of carbamazepine in the rat in vivo. Evidence for the formation of reactive arene oxide(s)","volume":"24","author":"Madden","year":"1996","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0135","series-title":"Clinical Biomedical and Hematological Reference Values in Normal Experimental Animals and Normal Humans","author":"Mitruka","year":"1981"},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0140","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1177\/0883073808318061","article-title":"Management and risk factors for dyslipidemia with the ketogenic diet","volume":"23","author":"Nizamuddin","year":"2008","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0160","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/jps.2600710136","article-title":"Comparison of equilibrium time in dialysis experiments using spiked plasma or spiked buffer","volume":"71","author":"\u00d8ie","year":"1982","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0145","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1097\/00005768-199711000-00005","article-title":"The poloxamer 407-induced hyperlipidemic atherogenic animal model","volume":"29","author":"Palmer","year":"1997","journal-title":"Med. Sci. Sports Exerc."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0150","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0090-9556(25)07380-5","article-title":"Comparative effects of carbamazepine and carbamazepine-10,11-epoxide on hepatic cytochromes P450 in the rat","volume":"24","author":"Panesar","year":"1996","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0155","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/ptr.2676","article-title":"Pharmacokinetic interaction of single dose of piperine with steady-state carbamazepine in epilepsy patients","volume":"23","author":"Pattanaik","year":"2009","journal-title":"Phytother. Res."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0165","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/ptr.2808","article-title":"Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp","volume":"23","author":"Qiu","year":"2009","journal-title":"Phytother. Res."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0170","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0090-9556(25)05982-3","article-title":"Disposition of carbamazepine and its 10,11-epoxide metabolite in the isolated perfused rat liver","volume":"5","author":"Rane","year":"1977","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0175","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1023\/A:1015872901523","article-title":"Dose-dependent pharmacokinetics of carbamazepine in rats: determination of the formation clearance of carbamazepine-10,11-epoxide","volume":"7","author":"Remmel","year":"1990","journal-title":"Pharm. Res."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0180","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/bdd.457","article-title":"Pharmacokinetics of amiodarone in hyperlipidemic and simulated high fat-meal rat models","volume":"26","author":"Shayeganpour","year":"2005","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0185","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijpharm.2008.05.019","article-title":"The impact of experimental hyperlipidemia on the distribution and metabolism of amiodarone in rat","volume":"361","author":"Shayeganpour","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0190","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2165\/00003088-199631030-00004","article-title":"Clinically significant pharmacokinetic drug interactions with carbamazepine. An update","volume":"31","author":"Spina","year":"1996","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0195","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1248\/bpb.32.269","article-title":"Pharmacokinetics of human immunodeficiency virus protease inhibitor, nelfinavir, in poloxamer 407-induced hyperlipidemic model rats","volume":"32","author":"Sugioka","year":"2009","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0200","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0090-9556(25)06571-7","article-title":"Metabolism of carbamazepine and its epoxide metabolite in human and rat liver in vitro","volume":"9","author":"Tybring","year":"1981","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0205","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11418-009-0350-8","article-title":"Antihyperlipidaemic activity of swertiamarin, a secoiridoid glycoside in poloxamer-407-induced hyperlipidaemic rats","volume":"63","author":"Vaidya","year":"2009","journal-title":"J. Nat. Med."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0210","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cpt1975184377","article-title":"Commentary: a physiological approach to hepatic drug clearance","volume":"18","author":"Wilkinson","year":"1975","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0215","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1007\/s12272-001-2152-8","article-title":"Anti-hyperlipidemic effect of an edible brown algae, Ecklonia stolonifera, and its constituents on poloxamer 407-induced hyperlipidemic and cholesterol-fed rats","volume":"31","author":"Yoon","year":"2008","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.euroneuro.2011.10.004_bb0220","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s11095-006-0071-6","article-title":"Hepatic CYP3A expression is attenuated in obese mice fed a high-fat diet","volume":"23","author":"Yoshinari","year":"2006","journal-title":"Pharm. Res."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X11002677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X11002677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T22:31:02Z","timestamp":1741991462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X11002677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0924977X11002677"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2011.10.004","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}